Quantbot Technologies LP Takes $386,000 Position in Arrowhead Pharmaceuticals, Inc. $ARWR

Quantbot Technologies LP bought a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 11,197 shares of the biotechnology company’s stock, valued at approximately $386,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Marshall Wace LLP increased its holdings in Arrowhead Pharmaceuticals by 3,507.8% in the 2nd quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock valued at $34,065,000 after buying an additional 2,096,238 shares during the period. Norges Bank bought a new position in shares of Arrowhead Pharmaceuticals during the 2nd quarter worth about $30,414,000. Vanguard Group Inc. lifted its holdings in shares of Arrowhead Pharmaceuticals by 3.3% during the 3rd quarter. Vanguard Group Inc. now owns 16,035,870 shares of the biotechnology company’s stock worth $553,077,000 after acquiring an additional 510,798 shares during the period. Invesco Ltd. boosted its position in shares of Arrowhead Pharmaceuticals by 142.8% during the 2nd quarter. Invesco Ltd. now owns 762,665 shares of the biotechnology company’s stock valued at $12,050,000 after acquiring an additional 448,585 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in shares of Arrowhead Pharmaceuticals by 34.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock valued at $22,189,000 after acquiring an additional 447,456 shares in the last quarter. 62.61% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, COO Patrick O’brien sold 49,493 shares of the stock in a transaction on Monday, January 5th. The stock was sold at an average price of $63.11, for a total transaction of $3,123,503.23. Following the sale, the chief operating officer owned 474,908 shares in the company, valued at approximately $29,971,443.88. This represents a 9.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider James C. Hamilton sold 40,164 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $63.11, for a total value of $2,534,750.04. Following the completion of the sale, the insider owned 171,958 shares of the company’s stock, valued at approximately $10,852,269.38. This trade represents a 18.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 495,836 shares of company stock worth $32,759,810 in the last three months. Company insiders own 3.60% of the company’s stock.

Analyst Upgrades and Downgrades

ARWR has been the subject of several recent research reports. B. Riley Financial increased their price target on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Piper Sandler reaffirmed an “overweight” rating and set a $110.00 price objective (up from $100.00) on shares of Arrowhead Pharmaceuticals in a report on Tuesday, January 13th. Royal Bank Of Canada upped their price objective on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the company an “outperform” rating in a research note on Thursday, December 11th. The Goldman Sachs Group increased their target price on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the stock a “neutral” rating in a report on Wednesday, January 7th. Finally, Weiss Ratings upgraded Arrowhead Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $81.67.

Arrowhead Pharmaceuticals Price Performance

NASDAQ:ARWR opened at $60.67 on Tuesday. The company has a quick ratio of 3.38, a current ratio of 3.38 and a debt-to-equity ratio of 0.29. The firm has a market cap of $8.50 billion, a PE ratio of 39.65 and a beta of 1.23. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $9.57 and a 12 month high of $76.76. The company’s 50-day moving average price is $65.28 and its two-hundred day moving average price is $50.57.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.38). The firm had revenue of $264.03 million during the quarter, compared to the consensus estimate of $225.66 million. Arrowhead Pharmaceuticals had a net margin of 18.54% and a return on equity of 35.64%. The business’s revenue was up 10461.3% on a year-over-year basis. During the same quarter last year, the firm posted ($1.39) EPS. On average, equities analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.